Theragen Bio selects the final institution for developing a customized anti-cancer vaccine for patients in the Korean ARPAH project

Aug 12, 2025

Theragen Bio selects the final institution for developing a customized anti-cancer vaccine for patients in the Korean ARPAH project



Terrazenbio has been selected as the final implementation institution for the task of the Korean ARPA-H Project promoted by the Ministry of Health and Welfare 'Building a Patient-Customized Anti-cancer Vaccine Development Platform (PAVE)'. The project is a large project with up to 19.1 billion won in research funds invested over 4.5 years.

The 'NeoVax-K Consortium', jointly participated by the dielectric analysis company Terrazenbio, aims to develop a patient-specific anti-cancer vaccine based on mRNA vaccine technology. Five organizations, including Aston Science, the organizer, Theragen Bio, IMBDX, GinEdit, and Korea University Anam Hospital, will participate.

In this project, Terrazenbio plans to analyze the dielectric data of pancreatic cancer patients and predict and verify new antigen candidates by using its own platform for new antigen vaccines such as ▲DeepOmicsFFPETM ▲ DeepOmicsNeoTM ▲ Double Barcode Neoepitope ScanTM. The company explained that its goal is to increase the prediction accuracy, which was less than 50% compared to the existing method, to more than 90%. In addition, it plans to develop an anticancer vaccine production process by applying an optimized mRNA structure and establish a small mRNA GMP production facility to support domestic bio companies' vaccine and treatment development infrastructure.




Baek Soon-myeong, CEO of Terrazenbio, said, "This PAVE project selection is the result of our efforts over the past four years. Through close cooperation with the members of the NeoVax-K consortium, we will develop treatments that can dramatically increase the survival rate of incurable cancers such as pancreatic cancer, CMS4 subtype colorectal cancer, and childhood and adolescent cancer, which lacked existing treatment alternatives."We will also contribute to the creation of an ecosystem of the domestic mRNA industry."

Meanwhile, the Korean ARPA-H project is a large-scale challenging research and development (R&D) project of the Korean government aimed at solving the challenges of national health care and implementing innovative health services, and was designed by benchmarking the Advanced Research Projects Agency for Health (ARPA-H) in the United States.






This article was translated by Naver AI translator.